Seaview Investment Managers’s Regeneron Pharmaceuticals REGN Stock Holding History

Seaview Investment Managers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,349	Closed	-$7.17M	–	114
2021 Q4	$7.17M	Buy	+11,349	New	+$6.98M	2.52%	21
2021 Q2	–	Sell	-7,443	Closed	-$3.52M	–	93
2021 Q1	$3.52M	Buy	7,443 +823	+12%	+$401K	2.58%	24
2020 Q4	$3.2M	Buy	6,620 +958	+17%	+$517K	2.24%	26
2020 Q3	$3.08M	Buy	+5,662	New	+$3.43M	2.83%	22

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seaview Investment Managers's REGN Position: Q1 2022 in Review

Seaview Investment Managers sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 11,349 shares — an estimated $7.17M sold.

Seaview Investment Managers first reported a position in REGN in Q3 2020 and held it in 4 quarters. The position peaked at $7.17M in Q4 2021. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Seaview Investment Managers reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Seaview Investment Managers sold 11,349 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $7.17M.
Seaview Investment Managers first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Seaview Investment Managers's Regeneron Pharmaceuticals position peaked at $7.17M in Q4 2021.
1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Seaview Investment Managers's 13F filing for Q1 2022, filed 28 Apr 2022.